GlassScriptPhysician profile
William C Winters
NPI 1124297296
$39,852.27
in general payments reported to CMS, 2019-2025
22 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $106 · 2021: $327 · 2022: $82.19 · 2023: $7,703 · 2024: $31K · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $31K · Travel and Lodging: $6,201 · Food and Beverage: $2,288 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $30,600.00 |
| Travel and Lodging | $6,200.73 |
| Food and Beverage | $2,287.86 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $37,276.34 | 2023-2024 | Lumryz |
| Abbvie INC. | $647.46 | 2021-2025 | Vraylar |
| Harmony Biosciences LLC | $455.74 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $282.38 | 2023-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $225.03 | 2022-2024 | Quviviq |
| Sunovion Pharmaceuticals INC. | $215.78 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $203.80 | 2019-2025 | Rexulti |
| Bausch Health US, LLC | $76.75 | 2022-2025 | Wellbutrin, Aplenzin |
| Lundbeck LLC | $69.54 | 2023-2025 | Rexulti |
| Allergan, INC. | $66.82 | 2019 | |
| Tris Pharma INC | $50.69 | 2023-2024 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $50.05 | 2025 | Fanapt |
| Corium, LLC | $44.94 | 2023-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $34.82 | 2019-2020 | |
| Almatica Pharma LLC | $32.36 | 2024 | Loreev Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $24.53 | 2024 | Spravato |
| Supernus Pharmaceuticals, INC. | $21.54 | 2024 | Qelbree |
| Collegium Pharmaceutical, INC. | $19.32 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $17.32 | 2021 | |
| Neurocrine Biosciences, INC. | $12.88 | 2022 | |
| Shire North American Group INC | $12.44 | 2019 | |
| Neos Therapeutics, LP | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Winters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.